Remains Confident in Company’s Standalone Opportunities – Given Strong Momentum and Near-Term Inflection Point Coming from Phase 3 Data “As the Company’s third-largest shareholder, we are deeply ...

Proposed 38% Premium Ranks Much Lower Than Average Premium of Approximately 89% for Comparable Biopharma Transactions since 2020 Believes Acceleron Has Significant Momentum Given Recent Positive Data ...

NEW YORK--(BUSINESS WIRE)--Avoro Capital Advisors (“Avoro”), a long-term and collaborative investor in life sciences and biotechnology companies, together with certain of its affiliates and managed ...

Avoro Capital, together with certain of our affiliates and managed funds, beneficially owns approximately 7% of Acceleron Pharma Inc., making us one of the Company's most significant shareholders.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Avoro Capital Advisors (formerly known as venBio Select ...

Avoro Capital’s Behzad Aghazadeh is among the most prominent investors in biotech, delivering consistent returns at his $6 billion hedge fund. Speaking with STAT’s Adam Feuerstein late last year about ...

NEW YORK--(BUSINESS WIRE)--Avoro Ventures, a global venture capital firm investing in life sciences, announced the final close of its inaugural fund, Avoro Ventures Fund L.P. (“The Fund”), with $186 ...

Copenhagen, Denmark, 10 January 2024 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of ...

NEW YORK--(BUSINESS WIRE)--Avoro Capital Advisors (“Avoro”), a long-term and collaborative investor in life sciences and biotechnology companies, together with certain of its affiliates and managed ...

Believes Company Has Strong Momentum and Continuing as Standalone Entity is Superior Path to a Transaction at the Proposed Price, Particularly with Major Value Inflection Point Coming from Phase 3 ...